Developing Therapies for Central Nervous System Diseases, such as Alzheimer’s Disease, as well as targeted Rare Diseases through our Platform Product, JOTROL™​. Patents in USA and Europe just approved. $1.76 million grant for Phase I in Alzheimer's Disease received from NIA/NIH.